High contrast targeted SWIR fluorescence tumor screening and resection with a commercially available dye

Here we have validated a commercially available dye, CJ215 from ProImaging for enhanced cancer delineation. The dye (which does not require antibody or peptide conjugation) was found to be effective for both NIR and SWIR fluorescence imaging methods in preclinical breast, fibrosarcoma and prostate tumor models. The dye was effective for screening and resection and achieved some of the best-in-class tumor to organ ratios, e.g., tumor to muscle of 88.1, to liver of 17.9, to lungs of 12.9 and to kidney of 5 highlighting its renal clearance method. We briefly summarize the proposed mechanism of uptake and highlight the potential for clinical translation.